Displaying 1 - 12 of 82
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

AKH: A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration - EASL SLD Summit 2025

View
Displaying 1 - 12 of 82